Ichnos Sciences
-
Ichnos Sciences in licensing agreement with Astria Therapeutics
Astria Therapeutics is granted global rights to develop and commercialise OX40 portfolio, comprised of Telazorlimab and its follow-on molecules, for…
Read More » -
Glenmark’s subsidiary Ichnos Sciences in licensing agreement with Almirall
Almirall is granted exclusive global rights to develop and commercialise ISB 880 for use in autoimmune diseases Ichnos Sciences, a…
Read More »